Targeting the IRAK1/4 signaling pathway has emerged as a promising therapeutic strategy for various malignancies, including diffuse large B-cell lymphoma (DLBCL), myelodysplastic syndrome, breast cancer, head and neck cancer, and pancreatic cancer. This evidence concerns the gene IRAK1 and pancreatic neoplasm.